BioNexus Gene Lab Corp Financial Ratios
BGLC|FY2025 SEC 10-K data
Includes DuPont ROE decomposition, profitability margins, liquidity ratios, solvency indicators, and earnings quality analysis. All ratios calculated from FY2025 SEC 10-K data.
Key Data Points
- Altman Z-Score 5.27 (safe zone, above 2.9 threshold)
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
DuPont ROE Decomposition (FY2025)
Return on Equity
-34.6%
Profit Margin
-40.2%
Net Income / Revenue
Asset Turnover
0.80
Revenue / Total Assets
Equity Multiplier
1.07
Total Assets / Equity
Composite: -34.6% (reported: -34.6%)
Profitability
Liquidity
Current Ratio
10.46
Quick Ratio
9.16
Solvency
Interest Coverage
-
Efficiency
Asset Turnover
0.80
Inventory Turnover
9.37
Days Sales Outstanding
25 days
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026
Earnings Quality
Accrual Ratio
-11.6%
-16.4pp YoY
Earnings are primarily supported by operating cash flow.
This metric is for informational purposes only and does not constitute investment advice. Data sourced from SEC EDGAR filings; updates may be delayed.